Join
Live feed
·
PRReleasevia Quantisnow
Perspective Therapeutics Inc. logo

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

ByQuantisnow·Wall Street's wire, on your screen.
CATX· Perspective Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CATX (Perspective Therapeutics Inc.) and more on Quantisnow.